Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2004

View Archived Issues

New peptide sulfonamides and their use as integrin receptor modulators

New antitumor agents and their use in ALL therapy

Novel glucagon antagonists covered by Merck patent

Phamacopeia scientists claim new IL-8 receptor modulators

Novartis presents new cathepsin S inhibitors with utility in neuropathic pain

Daiichi scientists prepare and test new factor Xa inhibitors

New antibacterial agent isolated from Fundibacter sp. by Japanese researchers

Merck KGaA grants vilazodone rights to Genaissance

European approval for Angiox for use in PCI

New perspectives in the use of sumatriptan to treat migraine

RGH-896 demonstrates in vivo analgesia

Lower infection rate found in some volunteers after receiving bivalent HIV vaccines

Patient recruitment starts in a phase I clinical trial with DAC:GRF

IND submission to begin clinical testing of Tarvacin

Clinical trials confirm the efficacy of ropinirole in PD and RLS

Advisory Committee recommends approval of Menactra

Long-term clinical evaluation of three treatments for early PD

Pivotal study begins for FavId for follicular B-cell NHL

NF-kappaB Decoy set to enter phase I/II trial in 2005

Canadian sites approved to join pivotal Veronate study

Promising early results for escitalopram in treatment of kleptomania

RegeneRx files to begin phase II study of TB4 for chronic pressure ulcers

Enrollment completed in phase III study of Canvaxin

Sopherion licenses North American rights to Myocet

Paladin Labs realigns product pipeline

Alimta approved in Europe for malignant pleural mesothelioma and NSCLC

Enrollment under way in Modrenal prostate cancer study

Sertraline demonstrates potential in treating bulimia

DNA vaccine for anthrax effective in rabbit model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 3, 2026